Recro Pharma, Inc: Kevin Kotler’s Broadfin Capital Bought Stake

March 19, 2018 - By Dolores Ford

 Recro Pharma, Inc: Kevin Kotler's Broadfin Capital Bought Stake

Investors sentiment decreased to 1.65 in Q3 2017. Its down 0.56, from 2.21 in 2017Q2. It worsened, as 7 investors sold Recro Pharma, Inc. shares while 10 reduced holdings. 5 funds opened positions while 23 raised stakes. 9.63 million shares or 4.72% less from 10.10 million shares in 2017Q2 were reported.

Amer Intl Gp Incorporated holds 0% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH) for 9,133 shares. Moreover, Deutsche Natl Bank Ag has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 12,601 shares. Broadfin Ltd Liability invested in 4.12% or 3.10M shares. Rhumbline Advisers reported 15,411 shares or 0% of all its holdings. The Georgia-based Advisory Svcs Ltd has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). 4,328 were reported by Bancshares Of Montreal Can. Manufacturers Life Co The holds 0% in Recro Pharma, Inc. (NASDAQ:REPH) or 140 shares. Moreover, Morgan Stanley has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH). Blackrock Inc holds 0% or 998,056 shares. Jpmorgan Chase & stated it has 21,784 shares. Legal & General Group Public Limited Co has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Vanguard Group Inc has 666,252 shares. Ameritas Investment Prtnrs Incorporated accumulated 0% or 1,196 shares. Alyeska Inv Group Inc Limited Partnership reported 906,398 shares or 0.07% of all its holdings. Schwab Charles Investment Mgmt holds 0% or 30,500 shares.

Since December 12, 2017, it had 0 insider purchases, and 7 selling transactions for $3.53 million activity. SCP Vitalife Partners II LP sold 38,810 shares worth $344,688. $2.01M worth of Recro Pharma, Inc. (NASDAQ:REPH) shares were sold by Broadfin Healthcare Master Fund Ltd. SCP Vitalife Partners (Israel) II – L.P. also sold $115,139 worth of Recro Pharma, Inc. (NASDAQ:REPH) on Tuesday, January 2.

The New Kevin Kotler’s Broadfin Capital Holding in Recro Pharma, Inc

Broadfin Capital reported SC 13D/A form with the SEC for Recro Pharma, Inc. Access it here: 000091957418002505. As reported by Kevin Kotler’s Broadfin Capital, the filler owns 11.67% or 2,236,025 shares of the Health Care–company.

Recro Pharma, Inc stake is new for [reportingPerson]. Date of activity: March 13, 2018. This shows Kevin Kotler’s Broadfin Capital’s positive view for Recro Pharma, Inc. For a hedge fund managing $1.26 billion in assets and having 10+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Kevin Kotler’s Broadfin Capital’s portfolio is in the sector.

Reasons Why Kevin Kotler’s Broadfin Capital Bought – Recro Pharma, Inc Stock

Purpose of Transaction

The Reporting Persons hold the securities described in Item 5 of this statement for investment purposes only.

No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) – (j) of Item 4 of Schedule 13D except as set forth herein. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer’s financial position and investment strategy, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, making proposals to the Issuer concerning changes to the capitalization, ownership structure or operations of the Issuer, purchasing additional Shares, selling some or all of their Shares, engaging in short selling of or any hedging or similar transaction with respect to the Shares or changing their intention with respect to any and all matters referred to in Item 4.

Recro Pharma, Inc Institutional Sentiment

Filings show 49 investors own Recro Pharma, Inc. The ownership in Q3 2017 is low, at Infinity of the outstanding shares. This is increased by 250671. 9627027 were owned by these investors. 5 funds opened new Recro Pharma, Inc stakes, 23 increased positions. There were 7 that closed positions and 10 reduced them.

Carl Domino Inc is an investor bullish on Recro Pharma, Inc, owning 28000 shares as of Q3 2017 for 0.31% of its portfolio. Opus Point Partners Management Llc owns 25231 shares or 0.20% of its portfolio. NY Broadfin Capital Llc have 4.12% of its portfolio for 3100086 shares. Further, Deerfield Management Company reported stake worth 0.77% of its portfolio. The IL Rothschild Investment Corp owns 25000 shares. Recro Pharma, Inc is 0.03% of its portfolio.

SEC Form 13D.

Kevin Kotler’s Broadfin Capital website.

Analysts await Recro Pharma, Inc. (NASDAQ:REPH) to report earnings on May, 10. They expect $-0.68 EPS, down 61.90 % or $0.26 from last year’s $-0.42 per share. After $-0.63 actual EPS reported by Recro Pharma, Inc. for the previous quarter, Wall Street now forecasts 7.94 % negative EPS growth.

The stock increased 5.70% or $0.6 during the last trading session, reaching $11.12. About 274,637 shares traded or 40.71% up from the average. Recro Pharma, Inc. (NASDAQ:REPH) has risen 26.61% since March 19, 2017 and is uptrending. It has outperformed by 9.91% the S&P500.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company has market cap of $213.03 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. It currently has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

Among 9 analysts covering Recro Pharma (NASDAQ:REPH), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma has $21 highest and $1100 lowest target. $16.38’s average target is 47.30% above currents $11.12 stock price. Recro Pharma had 16 analyst reports since August 25, 2015 according to SRatingsIntel. The stock of Recro Pharma, Inc. (NASDAQ:REPH) earned “Buy” rating by TH Capital on Friday, September 16. The stock has “Buy” rating by Roth Capital on Friday, September 16. On Thursday, July 20 the stock rating was maintained by Roth Capital with “Buy”. The company was initiated on Monday, October 3 by Brean Capital. Roth Capital maintained Recro Pharma, Inc. (NASDAQ:REPH) on Thursday, November 9 with “Buy” rating. Oppenheimer initiated Recro Pharma, Inc. (NASDAQ:REPH) rating on Tuesday, February 13. Oppenheimer has “Buy” rating and $19.0 target. The rating was initiated by H.C. Wainwright with “Buy” on Wednesday, September 2. The firm has “Buy” rating given on Monday, August 29 by Janney Capital. The firm has “Hold” rating by Zacks given on Tuesday, August 25. Piper Jaffray initiated Recro Pharma, Inc. (NASDAQ:REPH) rating on Monday, December 19. Piper Jaffray has “Overweight” rating and $12 target.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.